product summary
company name :
Cell Signaling Technology
product type :
antibody
product name :
Akt (pan) (40D4) Mouse mAb (HRP Conjugate)
catalog :
4298
clonality :
monoclonal
host :
mouse
conjugate :
HRP
clone name :
40D4
reactivity :
rat
application :
western blot
citations: 12
Published Application/Species/Sample/DilutionReference
  • western blot; rat; 1:1000; loading ...; fig 5g
Rong H, Zhao Z, Feng J, Lei Y, Wu H, Sun R, et al. The effects of dexmedetomidine pretreatment on the pro- and anti-inflammation systems after spinal cord injury in rats. Brain Behav Immun. 2017;64:195-207 pubmed publisher
Micel L, Tentler J, Tan A, Selby H, Brunkow K, Robertson K, et al. Antitumor activity of the MEK inhibitor TAK-733 against melanoma cell lines and patient-derived tumor explants. Mol Cancer Ther. 2015;14:317-25 pubmed publisher
Schrader A, Popal W, Lilienthal N, Crispatzu G, Mayer P, Jones D, et al. AKT-pathway inhibition in chronic lymphocytic leukemia reveals response relationships defined by TCL1. Curr Cancer Drug Targets. 2014;14:700-12 pubmed
Veeriah S, Leboucher P, de Naurois J, Jethwa N, Nye E, Bunting T, et al. High-throughput time-resolved FRET reveals Akt/PKB activation as a poor prognostic marker in breast cancer. Cancer Res. 2014;74:4983-95 pubmed publisher
Shivaswamy V, Bennett R, Clure C, Ottemann B, Davis J, Larsen J, et al. Tacrolimus and sirolimus have distinct effects on insulin signaling in male and female rats. Transl Res. 2014;163:221-31 pubmed publisher
Du Y, Teng X, Wang N, Zhang X, Chen J, Ding P, et al. NF-?B and enhancer-binding CREB protein scaffolded by CREB-binding protein (CBP)/p300 proteins regulate CD59 protein expression to protect cells from complement attack. J Biol Chem. 2014;289:2711-24 pubmed publisher
Li J, Huang J, Jeong J, Park S, Wei R, Peng J, et al. Selective TBK1/IKKi dual inhibitors with anticancer potency. Int J Cancer. 2014;134:1972-80 pubmed publisher
Liu C, Leclair P, Yap S, Lim C. The membrane-proximal KXGFFKR motif of ?-integrin mediates chemoresistance. Mol Cell Biol. 2013;33:4334-45 pubmed publisher
Aftimos P, Wiedig M, Langouo Fontsa M, Awada A, Ghanem G, Journe F. Sequential use of protein kinase inhibitors potentiates their toxicity to melanoma cells: a rationale to combine targeted drugs based on protein expression inhibition profiles. Int J Oncol. 2013;43:919-26 pubmed publisher
Keysar S, Astling D, Anderson R, Vogler B, Bowles D, Morton J, et al. A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins. Mol Oncol. 2013;7:776-90 pubmed publisher
RODRIGUEZ M, Potter D. CYP1A1 regulates breast cancer proliferation and survival. Mol Cancer Res. 2013;11:780-92 pubmed publisher
Strittmatter F, Walther S, Roosen A, Rutz B, Schlenker B, Limmer S, et al. Activation of protein kinase B/Akt by alpha1-adrenoceptors in the human prostate. Life Sci. 2012;90:446-53 pubmed publisher
product information
SKU :
4298S
Product-Name :
Akt (pan) (40D4) Mouse mAb (HRP Conjugate)
Size :
100 ul
Price-(USD) :
291 USD
Species-x-Reactivity :
H, M, R, Mk
Applications :
Western blot
Product-Category :
PI3K / Akt Signaling
Shipping-Temp :
COLD
Storage-Temp :
-20°C
Product-Type :
Monoclonal Antibody
MW :
60
Host :
Mouse
Target :
Akt1/Akt2/Akt3
company information
Cell Signaling Technology
3 Trask Lane
Danvers, MA 01923
info@cellsignal.com
https://www.cellsignal.com
8776162355
headquarters: USA
Established in Beverly, MA in 1999, Cell Signaling Technology (CST) is a privately-owned company with over 400 employees worldwide. We are dedicated to providing innovative research tools that are used to help define mechanisms underlying cell function and disease. Since its inception, CST has become the world leader in the production of the highest quality activation-state and total protein antibodies utilized to expand knowledge of cell signaling pathways. Our mission is to deliver the world's highest quality research tools that accelerate progress in biological research and personalized medicine.